<DOC>
	<DOCNO>NCT01187290</DOCNO>
	<brief_summary>The main objective trial compare feasibility efficacy sequential neoadjuvant chemoradiotherapy 44Gy concomitant boost neoadjuvant chemotherapy alone . Secondary objective ass value position emission tomography ( PET）in predict pathological response event-free survival（EFS）in stage IIIA non-small cell lung cancer ( NSCLC ) . Further compare amount serum DNA patient stage IIIa NSCLC , chemotherapy , radiotherapy ( arm A ) follow-up patient randomize trial correlate Deoxyribonucleic acid ( DNA ) variation tumor response , remission duration overall survival .</brief_summary>
	<brief_title>Preoperative Chemoradiotherapy Versus Chemotherapy Alone Nonsmall Cell Lung Cancer ( NSCLC ) Patients With Mediastinal Lymph Node Metastases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically proven NSCLC nodal metastasis : T13N2M0 Performance status 01 Patient medically fit enough protocol therapy , include operability Age 1875 Written inform consent No previous chemo radiotherapy Patients prior concomitant malignancy Allowed : nonmelanomatous skin cancer , adequately treat situ cervical cancer neoplastic disease diseasefree interval ³ 5 year . Presence history distant metastasis Unstable cardiac disease require treatment , congestive heart failure angina pectoris even medically control , significant arrhythmia , prior history myocardial infarction last 3 month History significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent Active uncontrolled infection Uncontrolled diabetes mellitus Gastric ulcer Preexisting peripheral neuropathy ( &gt; grade 1 ) Other serious underlie medical condition could impair ability patient participate trial Concurrent treatment experimental drug Pretreatment cytostatic therapy Previous radiotherapy chest Concurrent treatment prednisone ( equivalent ) except : prophylactic medication regimen treatment , treatment acute hypersensitivity reaction chronic treatment ( initiate &gt; 6 month prior trial entry ) low dose ( £ 20 mg methylprednisolone equivalent ) Definite contraindication use corticosteroids premedication Treatment within clinical trial within 30 day prior trial entry Socioeconomic geographic circumstance may prohibit proper staging , treatment followup procedure Pregnancy , lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Preoperative chemoradiotherapy</keyword>
	<keyword>stage IIIA , N2</keyword>
</DOC>